Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
Scientists are constantly looking for new ways to approach covid-19.
“Now the World Health Organization (WHO) recommends the use of interleukin-6 receptor blockers for the treatment of critically or critically ill patients with COVID-19, ”the agency published.
WHO considered to be one of the first remedies to be proven effective against covid-19 since September of last year, when the agency recommended corticosteroids.
People who are severely ill with the novel coronavirus usually suffer from an overreaction of the immune system, which can be very harmful to their health.
Interleukin-6 blockers (tocilizumab and sarilumab) work to suppress this reaction, WHO reveals.
Better numbers
“The updated guide for the management of patients with covid-19, who released the WHO this Tuesday, builds on the results of a prospective meta-analysis and a live network initiated by the same body, the largest such analysis on anticovid drugs to date, with data from more than 10,000 patients involved in 27 clinical trials ”, publishes the Rt agency.
The results of the meta-analysis showed that in critically ill or critically ill patients who receive these drugs, the risk of death is reduced by 13% compared to standard care. Additionally, the chance of needing mechanical ventilation is reduced by 28%.
However, the CEO of the WHODr. Tedros Adhanom Ghebreyesus lamented that although these drugs offer hope to patients and their families, “IL-6 receptor blockers remain inaccessible and inaccessible to most countries of the world” .
“Lower price”
To increase access, WHO calls on manufacturers to “reduce prices and make supplies available to low and middle income countries, especially where covid-19 is on the rise.”
In addition, WHO has invited producers of interleukin-6 receptor blockers to publish some type of expression of interest for the prequalification of innovative and biosimilar products, which aims to expand the availability of products from guaranteed quality and at lower prices thanks to the competition in the market. , “to meet urgent public health needs”.
Oms, Who, Rt.
.
[ad_2]
Source link
